key: cord-0333133-c8fza2b9
authors: Dogan, Mikail; Kozhaya, Lina; Placek, Lindsey; Karabacak, Fatih; Yigit, Mesut; Unutmaz, Derya
title: Targeting SARS-CoV-2 infection through CAR-T like bispecific T cell engagers incorporating ACE2
date: 2022-04-20
journal: bioRxiv
DOI: 10.1101/2022.01.19.476940
sha: d49f6de3ded8deeef39af12417c9370eb36f7b30
doc_id: 333133
cord_uid: c8fza2b9

Despite advances in antibody treatments and vaccines, COVID-19 caused by SARS-CoV-2 infection remains a major health problem resulting in excessive morbidity and mortality and the emergence of new variants has reduced the effectiveness of current vaccines. Here, as a proof-of-concept we engineered primary CD8 T cells to express SARS-CoV-2 Spike protein-specific CARs, using extracellular region of ACE2, and demonstrated their highly specific and potent cytotoxicity towards Spike-expressing target cells. To improve on this concept as a potential therapeutic, we developed a bispecific T cell engager combining ACE2 with an anti-CD3 scFv (ACE2-Bite) to target infected cells and the virus. Similar to CAR-T cell approach, ACE2-Bite endowed cytotoxic cells to selectively kill Spike-expressing targets. Furthermore, ACE2-Bite neutralized the pseudoviruses of SARS-CoV, SARS-CoV-2 wild-type and variants including Delta and Omicron, as a decoy protein. Remarkably, ACE2-Bite molecule showed a higher binding and neutralization affinity to Delta and Omicron variants compared to SARS-CoV-2 wild-type Spike proteins, suggesting the potential of this approach as a variant-proof, therapeutic strategy for future SARS-CoV-2 variants, employing both humoral and cellular arms of the adaptive immune response.

Worldwide, Coronavirus disease 2019 caused by SARS-CoV-2 infection has caused close to 6 million deaths and a chronic debilitating condition called Post-Acute COVID-19

Syndrome (PACS) in many millions more. An unprecedented effort by researchers around the world has resulted in the development of a spectrum of preventative and therapeutic approaches at an extraordinary speed. Vaccines focused on virus Spike protein (such as messenger RNA vaccines, non-replicating vector vaccines, and virus-like particle vaccines) are highly efficient in preventing infection (1) . Several therapeutic developments, such as synthetic neutralizing antibodies, monoclonal antibodies to Spike protein (2) (3), (4, 5) and immunomodulators such as corticosteroids (6, 7) , anti-IL-6 (8), anti-IL-1 (9) and Interferon-β-1a agents (10) were shown to have a range of treatment efficacy from non-effective to highly promising. Some of those treatments were repurposed to focus on blocking viral entry while others were used to control the hyperinflammatory immune response during the disease. Beyond antibody therapies, specific SARS-CoV-2 immunomodulators have not been developed yet are needed as specific antibodies potentially lose their effectiveness due to new variants. Therefore, the development of treatment approaches that remain effective against SARS-CoV-2 variants is of great interest.

SARS-CoV-2 uses its Spike protein to bind to the key host receptor Angiotensin-Converting Enzyme 2 (ACE2) on target cell surface for cell entry (11) and mutations in Spike protein result in higher affinity of the virus to ACE2 (12) and/or a better escaping mechanism from the immune system (13) . Following the cell entry, SARS-CoV-2 generates viral components by taking over the protein synthesis machinery of the host cell and displays Spike protein on the cell membrane (14) .

Using ACE2 molecule to target these Spike-expressing infected cells could be an effective strategy in preventative and therapeutic approaches to COVID-19 in the future since ACE2 receptor would have to be compatible to the binding of forthcoming mutant Spike proteins.

Here, we used a synthetic biology approach to engineer primary human CD8 T cells to express Spike protein-specific chimeric antigen receptors with ACE2 or anti-Spike antibody (ACE2 CAR or anti-Spike CAR) on the extracellular domain to target SARS-CoV-2 infected cells. Considering a viable strategy in clinical setting, we also engineered a novel ACE2/anti-CD3 bispecific T cell engager antibody (ACE2-Bite) to target both SARS-CoV-2 infected cells and the SARS-CoV-2

virus. Bispecific T cell engager antibodies (Bites) are engineered chimeric molecules that are designed to bind to CD3 on T cells via an anti-CD3 single chain variable fragment (ScFv) and to a target cell via a target-specific molecule. Upon bridging the T cells with a target cell, Bites trigger T cell activation and subsequent target cell apoptosis. CAR-T and bispecific T cell engager antibody approaches we developed in our study are similar to methods targeting cancer cells, several of which have been approved for treatment (15).

In this study, we show that ACE2-CAR and anti-Spike CAR-expressing CD8 T cells became activated and selectively killed different types of target cells expressing SARS-CoV-2 Spike protein on their surface. The ACE2-Bite antibodies also led to T cell activation in the presence of Spike expressing targets, and mediated cytotoxicity to these targets. In addition, ACE2-Bite antibodies acted as a decoy receptor for pseudoviruses incorporated with Spike proteins of Coronaviridae including SARS-CoV, SARS-CoV-2 wild-type, Delta and Omicron variants and neutralized these with a significantly increased affinity to Delta and Omicron. Taken together, these results suggest that the novel chimeric antigen receptors and bispecific antibodies may be used to re-direct cytotoxic immune cells towards SARS-CoV-2 infected host cells and to neutralize variant strains of the virus. 

All statistical analyses were performed, and graphs were prepared using GraphPad Prism V9

software. The numbers of repeats for each experiment were described in the associated figure legends.

Development of SARS-CoV-2 specific synthetic CARs expressed in T cells.

We sought to develop a system to test whether we can target cells that express SARS-CoV-2

Spike protein on their cell surface during the infection (16) (Figure 1A ) employing effector human T cells engineered to express CAR molecules that can recognize the Spike protein on cell surface.

For that, we transfected the cells with a plasmid containing a full-length wild-type Spike protein gene under CMV promoter ( Figure 1B) . Figure 1D ).

Next, we designed lentivector constructs containing ACE2 CAR or anti-Spike CAR cassettes followed by an Internal Ribosomal Entry Site (IRES) and Red Fluorescent Protein (RFP) and

transduced human primary CD8 T cells ( Figure 1E ) as previously described (19) . ACE2 CAR and anti-Spike CAR constructs comprised of CD8 alpha signal peptide, ACE2 extracellular domain (ECD) or anti-Spike ScFv, respectively, and intracellular 41BB co-stimulatory domain (CSD), and CD3ζ (zeta) signaling domains ( Figure 1E ). An Anti-CD19 CAR-RFP lentiviral construct was also designed to be used as a control. CD8 T cells were then activated and transduced with these lentiviruses encoding the CAR constructs and expanded in IL-2 for 10-12 days. Surface expression of ACE2 and anti-Spike was demonstrated on CAR engineered CD8 T cells, which also correlated with RFP reporter (Figure 1F ).

Cytotoxicity assays with ACE2 CAR and anti-Spike CAR expressing T cells.

We then co-cultured Spike+ target cell line and effector T cells expressing CARs and measured the cytotoxic activity of the T cells (Figure 2A) . Briefly, after the ~2-week proliferation of CAR-T cells, the cells were co-cultured for 72 hours with Spike-expressing target cells at different effector to target ratios. The CD8 T cells were then stained with anti-CD25 to determine their activation. 

SARS-CoV-2 Spike protein-expressing target cells.

Currently, the CAR-T cell immunotherapy procedure requires a meticulous process of collecting cells from patients, engineering them in a good manufacturing process environment, re-infusion, and extensive clinical follow-up of the patients (20) . As such this may not be very practical for treatment of COVID-19 patients. To overcome these hurdles of CAR-T approach, we engineered bispecific antibodies (Bites) as T cell activators, consisting of an anti-CD3 scFv fused with the extracellular domain of ACE2 to redirect CD3 T cells to SARS-CoV-2 infected cells ( Figure 3A) .

The ACE2-Bite cassette consisted of ACE2 signal peptide, ACE2 extracellular domain, a linker peptide, an anti-CD3 antibody single-chain variable fragment, a His-Tag, and a Hemagglutinin 

A major advantage of targeting the SARS-CoV-2 Spike protein through its receptor ACE2 using ACE2-Bite is that this approach is less affected by antibody escape mutations, as mutated Spike proteins would still need to interact with ACE2. In fact, it is conceivable that variants with increased affinity to ACE2 would bind better to ACE2-Bite, possibly improving its efficacy.

To test this with an ACE2-Bite/Spike affinity assay, we first employed our bead-based antibody detection strategy described in Figure 3 . In this experiment, we labelled the beads with wild-type and Omicron Spike protein trimers to determine the affinity of ACE2-Bites to natural trimeric Spike protein structure of these strains. Labelled beads were treated with ACE2-Bite and control supernatants in three-fold serial dilutions from 1 to 30 to generate titration curves. ACE2-Bite treated beads were then stained with recombinant CD3-Fc protein and anti-Fc antibody and analyzed via flow cytometry. Bead-based assay using these Spike protein trimers revealed a significant increase in affinity of ACE2-Bite molecule to Omicron Spike trimer compared to wildtype (p<0.0001) (Figures 4A, B) .

In addition to performing affinity assay on Spike-labeled beads, we also transduced 293 cells with GFP encoding lentivectors to express wild-type and Omicron variant Spikes and determined the ACE2-Bite affinity to these proteins on live target cells (Figure 4C) confirming the result of the bead-based affinity assay (Figures 4D, E) . Taken together, these results implicate the potential pan-SARS-CoV-2 effectivity of ACE2-Bite approach, even further, possibly higher efficiency of the neutralization and T cell cytotoxicity, as the virus evolves into variants with higher affinity towards ACE2 protein.

In addition to bridging infected cells to activate T cells, we reasoned that ACE2-Bite may also neutralize SARS-CoV-2 by binding to Spike proteins on the virus. To test this, we generated a set of lentiviruses pseudotyped with SARS-CoV, SARS-CoV-2 wild-type, Delta, and Omicron Spike proteins and investigated ACE2-Bite neutralization on these viruses. Neutralization assay was performed by pre-culturing pseudotyped viruses with different dilutions of ACE2-Bite supernatant and then adding to ACE2 expressing 293 cells as previously described (21) (Figure 5A) . We also 

Despite advances in vaccine development, COVID-19 is still a major cause of morbidity and mortality in the USA and throughout the world. Rapid evolution of the virus is also a major concern, suggesting the need to develop novel effective treatment strategies, as SARS-CoV-2 specific the spread of the virus in vivo. Another major advantage of the ACE2-Bite approach is using ACE2, the key host receptor of SARS-CoV-2, as the Spike protein recognizing part of the bispecific antibody. As shown in Figure 4 , this allowed us to target mutated Spike proteins from variants of concern with even better efficiency in contrast to conventional antibody approaches which lose their efficiency due to immune escape mutations (13) .

In addition to recognizing mutated Spike proteins, we found that ACE2 part of the ACE2-Bite functioned as a decoy receptor and neutralized the virus, preventing it from infecting the cells. patient resulted in dramatic decrease in viral copies in the patient plasma (44) . Other studies also demonstrated the neutralization capacity of soluble ACE2 molecule (45) (46) (47) . Considering the immunity of ACE2 to the Spike mutations, both as a CD3 T cell redirecting molecule and a decoy receptor, the efficacy of the ACE2-Bite treatment is unlikely to be diminished by variants arising during COVID-19 pandemic or in possible future SARS pandemics.

If these approaches are developed as therapeutics, it will also be important to consider side effects of CAR-T cells or ACE2-Bite treatment, cytokine release syndrome and T cell exhaustion, similar to cancer focused CAR-T therapies (48) . Although, we think this will be less likely given the number of infected cells would be expected to be much smaller compared to tumor burden;

overall, much fewer T cells would be stimulated during the infection. Another potential downside could be that the ACE2 in ACE2-Bite may interact with its physiologic ligands and interfere with the renin-angiotensin system, although, so far recombinant human ACE2 molecule has been tested in 89 patients with tolerable clinical outcomes (49, 50) . Regardless, if this becomes a problem it can be prevented by mutating the carboxypeptidase activity of ACE2. Furthermore, 20 downregulation of ACE2 levels due to SARS-CoV-2 binding during COVID-19 is associated with hyperactivation of renin-angiotensin system and injuries to the lung, kidneys, and heart (51) . Thus, ACE2-Bite may even have beneficial properties as a replacement to wild-type ACE2 activity during COVID-19.

In conclusion, engineered CD8 T cells expressing Spike protein-specific chimeric antigen receptors and ACE2/anti-CD3 bispecific T cell engagers developed in this study could be used to target SARS-CoV-2 infected host cells and the virus itself, and may be alternative future therapeutic strategies for COVID-19. 

Evaluation of the safety profile of COVID-19 vaccines: a rapid review

antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Mild or Moderate Covid-19

Dexamethasone in Hospitalized Patients with Covid-19

Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab

Anakinra for severe forms of COVID-19: a cohort study

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics

SARS-CoV-2 variants, spike mutations and immune escape

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas

Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation

A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition

Implications for the Design of Spike-Based Vaccine Immunogens

Probing the effector and suppressive functions of human T cell subsets using antigen-specific engineered T cell receptors

CAR-T cell therapy: current limitations and potential strategies

SARS-CoV-2 specific

CAR T cells for infection, autoimmunity and allotransplantation

Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects

Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a reengineered CD4-based chimeric antigen receptor

costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus

T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor

T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo

Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection

Off-the-shelf' allogeneic CAR T cells: development and challenges

Approaches, Progress, and Challenges to Hepatitis C Vaccine Development

An HIV vaccine--challenges and prospects

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

A novel asymmetrical anti

HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys

BiTE(R)), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

T cellengaging BiTE antibodies specific for EGFR potently eliminate KRAS-and BRAF-mutated colorectal cancer cells

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1(+) tumor cells, and extends the survival of tumor-bearing humanized mice

A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells

Human recombinant soluble ACE2 in severe COVID-19

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. bioRxiv

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

BiTEs better than CAR T cells

Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Lentiviruses expressing ACE2-Bite were used to transduce suspension 293 cells that produce and secrete ACE2-Bite protein in their culture supernatant. (C) Illustration of the bead-based ACE2-Bite capture assay. Fluorescent beads coated with Spike protein trimer or Spike-Receptor binding domain (S-RBD) were used to capture ACE2-Bite molecules which were detected via a recombinant CD3-Fc fusion protein and an anti-Fc antibody then subsequently analyzed by flow cytometry. ACE2-Fc molecules were also detected with Spike trimer or S-RBD coated beads and anti-Fc antibody. (D) Detection of different concentrations of ACE2-Bite (1:10 and 1:300 dilutions were shown in orange and turquoise, respectively) and ACE2-Fc (3 μg/mL) (red) using bead-based ACE2-Bite capture assay. Wild-type 293 cell supernatant (Control supe, Blue) and staining buffer (None, Pink) were used as negative controls. (E) Binding of ACE2-Bite to Spike-GFP expressing T2 cell line and primary human T cells. HA staining of Spike-GFP expressing T2 cells (top panel) and CD8 T cells (bottom panel) when combined with ACE2-Bite (right plot) or control (non-transduced 293) (left plot) supernatants. (F) CD25 and GFP expressions show activation and cytotoxicity of resting CD8 T cells against Spike/GFP-expressing or control (transduced with GFP-expressing empty vector) 293 cells in the presence of ACE2-Bite or control supernatant. The experiments were replicated with similar results. Figure 4: Binding of ACE2-Bite to variant Spike proteins (A) Bead-based ACE2-Bite/Spike binding assay. Beads were coated with full length SARS-CoV-2 wild-type and omicron variant Spike protein trimers and treated with ACE2-Bite and control media in three-fold serial dilutions from 1 to 30

The research in this study was supported by National Institute of Health (NIH) grant U19 AI142733-01 (DU) and Achelis and Bodman Foundation (DU). We thank Courtney Gunter and Sara Cassidy for critical reading and Mustafa Semih Elitok for advice on designing anti-Spike antibody ScFv protein.

The source data for the Figures All unique/stable reagents generated in this study are available from the lead contact with a completed materials transfer agreement